ITM2A

Across TCGA pan-cancer cohorts, ITM2A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ITM2A data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ITM2A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ITM2A expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where ITM2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.991	0.688	.006	15	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.227	.024	10	view →
HNSC	DFS	Median	III,IV	0.385	0.856	.017	6	view →
GBM	DFS	Median	All	0.791	0.644	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ITM2A–PDAC (DFS)

Open the PDAC breakdown →